Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

Enliven said it has reached FDA alignment on the final design of ENABLE-2, a planned Phase 3 trial of relcobatinib in approximately 450 adults with previously treated CML, and remains on track to begin the trial before year-end 2026. The study will compare relcobatinib 80 mg once daily with an investigator-selected second-generation TKI; its primary endpoint is major molecular response at Week 24. The company said an improvement of at least 10 percentage points in MMR versus control would be sufficient to demonstrate statistical superiority; efficacy and approval remain uncertain.

Analysis

FDA agreement reduces design and regulatory uncertainty, but does not validate relcobatinib’s efficacy or establish the company’s stated 10-percentage-point treatment-effect assumption. The randomized active-comparator design is strategically useful: a positive result would support differentiation against therapies physicians already use, while a merely comparable result could leave Enliven with a difficult commercial case in a mature treatment category. Even superiority on Week 24 MMR may not translate into durable share unless tolerability, discontinuations, and Week 96 response support a meaningful patient or prescriber advantage.

The immediate read-through is modestly positive for ELVN’s execution credibility; the larger valuation driver remains clinical data, not the trial-design announcement. Over the next 1–3 months, monitor actual trial initiation and enrollment signals, plus the remaining ENABLE dataset and any safety or dose-tolerability updates. Over 6–18 months, enrollment pace, durability, and funding capacity matter more than the nonproprietary name or management’s best-in-class framing. The release provides no independent efficacy confirmation, commercial pricing evidence, or cash-runway detail. A slower-than-planned start, a weaker-than-assumed comparator response, or adverse safety findings could undermine the thesis; financing needs could also dilute shareholders before pivotal results.

Key Decisions for Investors

• Treat the announcement as an execution de-risking event, not a clinical read-through. Avoid chasing a sharp ELVN pop; consider only a small, risk-budgeted position after checking current valuation, cash runway, and the latest ENABLE efficacy and safety data.
• Set a catalyst watch for trial initiation and enrollment progress. Reassess exposure if initiation slips beyond year-end 2026 or company updates imply enrollment or retention problems; verify timing directly rather than assuming a start date guarantees rapid recruitment.
• For a more conservative stance, wait for additional patient-level or trial data before taking directional exposure. The key thesis test is whether efficacy is accompanied by acceptable tolerability and durable response—not just the statistical superiority threshold at Week 24.
• Falsify the bullish view on materially unfavorable safety/tolerability updates, a meaningful delay to trial start, or evidence that the anticipated active-comparator advantage is not holding. Recheck financing runway and potential capital needs before sizing any position.